Mutant simplex virus for treating unwanted hyperproliferative cell growth
CA 2382998 A1 · Owner: Onyx Pharmaceuticals, Inc. · Inventors: Hermiston, Terry; Laquerre, Sylvie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to pharmaceutical compositions kits, and , methods of use thereof, comprising a mutant human herpes simplex-type 1 , virus which is cytopathic to susceptible hyperproliferative cells such as , neoplastic cells. Preferably the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 8, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.